Materials and Methods: A total of 187 patients that underwent radical inguinal orchiectomy due to the diagnosis of testicular tumor were included in Group 1and 128 patients of similar age that underwent varicocelectomy using a similar incision in Group 2 as controls. Hematological and biochemical blood results were collected one day before radical orchiectomy. The parameters of NLR (neutrophil/ lymphocyte counts), PLR (neutrophil/ lymphocyte counts), PLR (platelet/ lymphocyte counts), and LMR (lymphocyte/ monocyte counts) were expressed as the ratios of indicated blood cell components. Following standard inguinal radical orchiectomy, T staging was performed based on the final histology samples, and clinical N and M staging using imaging modalities.
Results: The mean (± SD) ages of the patients were 26.5±7.1, and 25.1±8.1 years for Groups 1 and 2, respectively. The neutrophil counts, NLR, and PLR were significantly higher in Group 1, while the lymphocyte count, MPV, and LMR were significantly higher in Group 2 (p<0.001 for all). LMR was also significantly higher in patients with T1 stage TM, and NLR in those with >T1 stage TM (p<0.001). There was no significant difference between the patients with T1 and >T1 in terms of MPV and PLR.
Conclusion: We determined NLR and LMR as parameters that can be used in the pathological staging of cases with TM. We consider that these hematological parameters have an important place in predicting the prognosis in this patient group.
In patients with TM, contrast-enhanced thoracoabdominal computed tomography (CT) was performed and serum tumor marker tests [alpha fetoprotein (AFP), lactate dehydrogenase (LDH), and beta-human chorionic gonadotropin (beta-HCG)] were carried out for staging after radical inguinal orchiectomy. After standard inguinal radical orchiectomy, T staging was performed on final histology samples, and clinical N and M staging was made using imaging modalities. Hematological and biochemical blood test results were collected one day before radical orchiectomy as part of our routine preoperative evaluation. Tumor markers were collected at one week and one month after radical orchiectomy to determine the final definitive staging.
Venous blood samples were taken into tubes containing ethylenediaminetetraacetic acid for laboratory tests. The neutrophil count, lymphocyte count, mean erythrocyte volume, and erythrocyte distribution width were measured using the Beckman Coulter DXH 780 device, and AFP, beta-hCG, and LDH were analyzed using Beckman Coulter DxI 800. NLR (neutrophil/ lymphocyte counts), PLR (platelet/lymphocyte counts, and LMR (lymphocyte/monocyte counts) were expressed as the ratios of indicated blood cell components.
Statistical Analysis
Categorical data were presented as numbers and percentages.
Normally distributed numerical data were shown as mean and
standard deviation, and non-normally distributed numerical
data as median (interquartile range) values. The Kolmogorov-
Smirnov test was used to test the normality of the distribution
of numerical data. Student"s t-test was conducted to compare
normally distributed numerical data. The frequencies of
categorical variables were compared with the Pearson chi-square
and Fisher"s exact tests. A p value below 0.05 was considered
statistically significant. Statistical analyses were performed
using the Statistical Package for the Social Sciences version 21
(IBM SPSS Statistics; IBM Corp., Armonk, NY, USA).
The neutrophil, lymphocyte, monocyte, platelet, MPV, NLR, LMR, and PLR values of the patients in Groups 1 and 2 were evaluated to compare hematological parameters. The neutrophil count, NLR, and PLR were statistically significantly higher in Group 1, while the lymphocyte count, MPV, and LMR were statistically significantly higher in Group 2 (p<0.001 for all). The data on comparison of hematological parameters are shown in Table 2.
Table 2. Comparison of hematological data between the study groups
Considering the pathological data of the patients with TM, seminoma was the most common histological type, seen at a rate of 58.3%, followed by mixed germ cell tumors. The tumor stage was T1 in 49.2%, T2 in 45.5%, and T3 in 5.3% of the patients. Lymph node metastasis was not observed in 48.1% of the patients. During the follow-up, metastases outside the lymph node were detected in 11.2% of the patients. Table 3 presents the data on the pathological and follow-up results of the patients with TM.
Table 3. Summary of pathological and follow-up results of Group 1
The relationship between the hematological data and T stages was compared. LMR was statistically significantly higher in the patients with T1 stage TM, while NLR was statistically significantly higher in those with >T1 pathologies. There was no significant difference between the T1 and >T1 cases in terms of MPV and PLR. The hematological data of the patients and their comparisons are given in Table 4.
MPV is not just a marker reflecting platelet counts. It is defined as an index of bioactive platelets that are activated and participate in the inflammatory process [14]. Yun et al. [15] reported that reduced MPV showed poor prognosis in renal cell cancer. However, Sahin et al., [16] stated that MPV could not be used as a prognostic factor in patients with stage T1-T2-T3 TM. In our study, when the control and TM groups were compared, MPV was found to be statistically significantly lower in patients with TM, but without any statistically significant difference between stage T1 and >T1 cases in terms of MPV values. Although MPV was lower in patients with TM, we do not think that it can be used as a prognostic factor in this malignancy.
In a meta-analysis of 100 studies including 40,559 patients, Templeton et al., [6] showed a strong association between NLR and the presence of more than 20 solid tumors. Although this analysis includes a very heterogeneous group of malignancies, it reflects the essential role of NLR in inflammation and immune suppression in cancer biology. Yuksel et al. [17] compared preoperative NLR values between patients with localized testis germ cell tumors and those with varicoceles as controls and found that NLR was significantly higher in patients with TM. Jankovich et al. [18] compared NLR values between patients with T1 and >T1 pathologies and determined higher NLR values in those with >T1 cancer. In our study, in which we also included the patients that underwent varicocelectomy in the control group, we found the NLR value to be statistically significantly higher in the patients with TM. In addition, the patients with a >T1 pathology result had significantly higher NLR values. Based on these findings, we can state that NLR is increased in patients with TM compared to healthy individuals and in those with stage >T1TM.
In a meta-analysis of 17 studies including 5,552 patients, Li et al., [19] determined that high preoperative LMR was associated with a favorable prognosis and concluded that it could be a potential prognostic biomarker in patients with urological cancer. However, in the literature, studies investigating the relationship between TM and LMR are very limited in number. Herraiz-Raya et al. [20] found that a LMR value of >3 in patients with TM indicated smaller tumor volume and lower cancer stage. In our study, lower LMR values were found in the patients with TM than in the varicocele control group. We also determined that LMR values statistically significantly differed between the patients with T1 and >T1 pathological stages. These results suggest that LMR decreases in patients with TM and in those with a higher pathological stage.
In their meta-analysis, Li et al., [19] detected lower PLR values in healthy individuals than in patients with urological tumors except those with bladder cancer. In addition, the authors observed that survival rates were lower in patients with higher PLR values. In another study where TM and varicocele groups were compared, Sahin et al., [16] could not find any significant difference between both groups in terms of PLR values. In the current study, we detected a statistically significantly higher PLR values in TM group compared to the healthy varicocele group, but we did not find a statistically significant difference between cases in stages T1 and >T1 regarding PLR values. Therefore, we consider that increased PLR can be used as a parameter in patients with TM, but it cannot provide information about staging.
The limitations of our study include its retrospective and single-center design, limited sample size, and absence of a prognostic predictive analysis.
Ethics Committee Approval: Ethics committee approval was received for this study from the ethics committee of University of Health Sciences, Dr. Sadi Konuk Training and Research Hospital (approval date and number: 07.03.2022/86).
Informed Consent: Written informed consent was obtained from patients who participated in this study.
Publication: The results of the study were not published in full or in part in form of abstracts.
Peer-review: Externally peer-reviewed.
Authorship Contributions: Any contribution was not made by any individual not listed as an author. Concept – I.E., M.E.; Design – I.E., Y.A., D.N.O., M.E.; Supervision – I.E., M.E.; Resources – I.E., M.E.; Materials – Y.A., D.N.O.; Data Collection and/or Processing – Y.A., M.E.; Analysis and/or Interpretation – I.E., D.N.O.; Literature Search – Y.A., D.N.O; Writing Manuscript – I.E., Y.A., D.N.O., M.E.; Critical Review – I.E., M.E.
Conflict of Interest: The authors declare no conflict of interest.
Financial Disclosure: The authors declare that this study received no financial support.
1) Brandt MP, Ruf C, Dieckmann KP, Syring I, Ruckes C,
Nestler T, et al. Clinical characteristics, treatment patterns
and relapse in patients with clinical stage IS testicular
cancer. World J Urol 2022;40:327-34.
https://doi.org/10.1007/s00345-021-03889-x
2) Imamoglu GI, Eren T, Baylan B, Karacın C. May High
Levels of Systemic Immune-Inflammation Index and
Hematologic Inflammation Markers Suggest a Further
Stage in Testicular Tumours? Urol Int 2019;103:303-10.
https://doi.org/10.1159/000502658
3) Kawanishi S, Hiraku Y, Pinlaor S, Ma N. Oxidative
and nitrative DNA damage in animals and patients with
inflammatory diseases in relation to inflammation-related
carcinogenesis. Biol Chem 2006;387:365-72.
https://doi.org/10.1515/BC.2006.049
4) Gakis G, Todenhöfer T, Stenzl A. The prognostic value
of hematological and systemic inflammatory disorders in
invasive bladder cancer. Curr Opin Urol 2011;21:428-33.
https://doi.org/10.1097/MOU.0b013e32834966fa
5) Mjaess G, Chebel R, Karam A, Moussa I, Pretot D, Abi Tayeh G,
et al. Prognostic role of neutrophil-to-lymphocyte ratio (NLR) in
urological tumors: an umbrella review of evidence from systematic
reviews and meta-analyses. Acta Oncol 2021;60:704-13.
https://doi.org/10.1080/0284186X.2021.1886323.
6) Templeton AJ, McNamara MG, Šeruga B, Vera-Badillo FE,
Aneja P, Ocaña A, et al. Prognostic role of neutrophil-tolymphocyte
ratio in solid tumors: a systematic review and
meta-analysis. J Natl Cancer Inst 2014;106:dju124.
https://doi.org/10.1093/jnci/dju124
7) Gokcen K, Dundar G, Gulbahar H, Gokce G, Gultekin EY.
Can routine peripheral blood counts like neutrophil-tolymphocyte
ratio be beneficial in prediagnosis of testicular
cancer and its stages? J Res Med Sci 2018;23:64.
https://doi.org/10.4103/jrms.JRMS_1009_16
8) Fankhauser CD, Sander S, Roth L, Gross O, Eberli D, Sulser
T, et al. Systemic inflammatory markers have independent
prognostic value in patients with metastatic testicular germ
cell tumours undergoing first-line chemotherapy. Br J
Cancer 2018;118:825-30.
https://doi.org/10.1038/bjc.2017.467
9) Wang J, Liu Y, Zhang N, Li X, Xin P, Bi J, et al. Prognostic
role of pretreatment platelet to lymphocyte ratio in urologic
cancer. Oncotarget 2017;8:70874-82.
https://doi.org/10.18632/oncotarget.20147
10) Sonpavde G, Pond GR, Armstrong AJ, Clarke SJ, Vardy JL,
Templeton AJ, et al. Prognostic impact of the neutrophil-tolymphocyte
ratio in men with metastatic castration-resistant
prostate cancer. Clin Genitourin Cancer 2014;12:317-24.
https://doi.org/10.1016/j.clgc.2014.03.005
11) Keizman D, Ish-Shalom M, Huang P, Eisenberger MA, Pili R,
Hammers H, et al. The association of pre-treatment neutrophil
to lymphocyte ratio with response rate, progression free survival
and overall survival of patients treated with sunitinib for
metastatic renal cell carcinoma. Eur J Cancer 2012;48:202-8.
https://doi.org/10.1016/j.ejca.2011.09.001
12) Dalpiaz O, Ehrlich GC, Mannweiler S, Hernández JM,
Gerger A, Stojakovic T, et al. Validation of pretreatment
neutrophil-lymphocyte ratio as a prognostic factor in a
European cohort of patients with upper tract urothelial
carcinoma. BJU Int 2014;114:334-9.
https://doi.org/10.1111/bju.12441
13) Krane LS, Richards KA, Kader AK, Davis R, Balaji KC,
Hemal AK. Preoperative neutrophil/lymphocyte ratio
predicts overall survival and extravesical disease in patients
undergoing radical cystectomy. J Endourol 2013;27:1046-
50.
https://doi.org/10.1089/end.2012.0606
14) Gasparyan AY, Ayvazyan L, Mikhailidis DP, Kitas GD.
Mean platelet volume: a link between thrombosis and
inflammation? Curr Pharm Des 2011;17:47-58.
https://doi.org/10.2174/138161211795049804
15) Yun ZY, Zhang X, Liu ZP, Liu T, Wang RT, Chen H.
Association of decreased mean platelet volume with renal
cell carcinoma. Int J Clin Oncol 2017; 22;1076-80.
https://doi.org/10.1007/s10147-017-1158-2
16) Şahin A, Toprak T, Kutluhan MA, Vural Y, Ürkmez A,
Verit A. Increased neutrophil/lymphocyte ratio in testicular
cancer. Arch Ital Urol Androl 2019;91:97-101.
https://doi.org/10.4081/aiua.2019.2.97
17) Yuksel OH, Verit A, Sahin A, Urkmez A, Uruc F. White
blood cell counts and neutrophil to lymphocyte ratio in the
diagnosis of testicular cancer: a simple secondary serum
tumor marker. Int Braz J Urol 2016;42:53-9.
https://doi.org/10.1590/S1677-5538.IBJU.2014.0593
18) Jankovich M, Jankovichova T, Ondrus D, Breza J.
Neutrophil-to-lymphocyte ratio as a predictor of
preoperative tumor staging in testicular germ cell tumors.
Bratisl Lek Listy 2017;118:510-2.
https://doi.org/10.4149/BLL_2017_098